Nevro Corp (NYSE:NVRO) CFO Andrew H. Galligan sold 17,718 shares of the company’s stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $120.11, for a total transaction of $2,128,108.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Andrew H. Galligan also recently made the following trade(s):

  • On Monday, January 6th, Andrew H. Galligan sold 2,782 shares of Nevro stock. The stock was sold at an average price of $120.00, for a total transaction of $333,840.00.
  • On Monday, November 25th, Andrew H. Galligan sold 12,000 shares of Nevro stock. The stock was sold at an average price of $110.39, for a total transaction of $1,324,680.00.
  • On Monday, November 11th, Andrew H. Galligan sold 18,522 shares of Nevro stock. The stock was sold at an average price of $103.70, for a total transaction of $1,920,731.40.

Shares of NVRO stock traded down $0.70 during trading hours on Friday, hitting $117.31. The stock had a trading volume of 553,773 shares, compared to its average volume of 422,171. The firm has a market capitalization of $3.60 billion, a PE ratio of -71.53 and a beta of 0.38. Nevro Corp has a twelve month low of $38.40 and a twelve month high of $120.74. The stock’s 50 day moving average is $113.62 and its 200 day moving average is $88.31. The company has a debt-to-equity ratio of 0.91, a current ratio of 5.87 and a quick ratio of 4.54.

Nevro (NYSE:NVRO) last posted its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported ($0.58) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.85) by $0.27. The business had revenue of $100.16 million during the quarter, compared to the consensus estimate of $92.27 million. Nevro had a negative return on equity of 46.35% and a negative net margin of 25.94%. The company’s revenue was up 4.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.37) earnings per share. As a group, equities analysts predict that Nevro Corp will post -3.69 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the company. Amundi Pioneer Asset Management Inc. purchased a new stake in shares of Nevro during the first quarter worth approximately $1,525,000. Prudential Financial Inc. purchased a new stake in shares of Nevro during the second quarter worth approximately $202,000. Russell Investments Group Ltd. purchased a new stake in shares of Nevro during the second quarter worth approximately $5,933,000. Bank of Montreal Can raised its stake in shares of Nevro by 327.3% during the second quarter. Bank of Montreal Can now owns 5,183 shares of the medical equipment provider’s stock worth $336,000 after purchasing an additional 3,970 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Nevro by 2.8% during the second quarter. Charles Schwab Investment Management Inc. now owns 176,781 shares of the medical equipment provider’s stock worth $11,461,000 after purchasing an additional 4,801 shares during the last quarter.

A number of equities analysts recently issued reports on the company. Wells Fargo & Co upped their price target on Nevro from $86.00 to $105.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Morgan Stanley upped their price target on Nevro from $100.00 to $125.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. ValuEngine downgraded Nevro from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. SunTrust Banks assumed coverage on Nevro in a report on Tuesday. They issued a “buy” rating and a $132.00 price objective for the company. Finally, JMP Securities increased their price objective on Nevro to $115.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Six equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $94.83.

About Nevro

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Featured Article: Diversification in Your Portfolio

Insider Buying and Selling by Quarter for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.